Hikma continues strong 2021 performance and reiterates full year guidance

London, 4 November 2021 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Press Release Corporate 4 November 2021

Siggi Olafsson, Hikma’s CEO, said: “Our business continues to perform strongly, enabling us to reiterate our full year guidance to achieve another year of growth. We have made excellent progress year to date, including launching new specialty products, establishing new partnerships and using our robust balance sheet to expand our portfolio and pipeline. While the global pandemic continues to bring some volatility, we are leveraging our resilient commercial and operational capabilities to drive growth and to reliably deliver medicines to our customers and patients.”   



Our global Injectables business is performing well. In the US, we remain on track to deliver growth for the full year, benefitting from the breadth of our portfolio, which is now over 120 products and includes 14 products launched in the year to date. While elective surgeries remain below pre-pandemic levels, our flexible, high quality manufacturing capabilities and resilient supply chain continue to underpin our ability to provide a consistent supply of medicines to our customers.

We are also making good strategic progress in the US, where we recently announced our first US biosimilar partnership – an exclusive licensing agreement with Bio-Thera to commercialise their proposed biosimilar referencing Stelara® (ustekinumab). In addition, we have agreed to acquire Custopharm, a US-based generic sterile injectables company with a differentiated product portfolio and R&D pipeline. The transaction is subject to US Federal Trade Commission approval.

In Europe, we are delivering strong growth from our own products, including some COVID-19 related medicines. We also continue to utilise our flexible manufacturing capacity for contract manufacturing opportunities. In MENA, we are seeing good demand across most of our markets and are increasing our investment in the expansion of local manufacturing capacity.

We continue to expect global Injectables revenue to grow in the mid-single digits and core operating margin to be in the range of 37% to 38%.



Our Generics business is continuing the strong performance seen in the first half. This reflects good performance from our in-market products as well as a strong contribution from recent launches, which are more than offsetting expected price erosion on our base business.

We are making good progress expanding our portfolio and pipeline for this business, especially with respect to our specialty portfolio, which will be an increasingly important driver of future growth. In August we launched KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg, which has received good feedback in the community health and addiction therapy market. We are also building our portfolio of specialty allergy treatments, signing an exclusive license agreement with FAES Farma S.A. in September to commercialise Bilastine tablets, a non-sedating second generation antihistamine.

We continue to expect our full year Generics revenue to be in the range of $810 million to $830 million and we now expect core operating margin to be closer to the top end of our guidance range of 22% to 24%, reflecting a more favorable product mix.



The Branded business is performing well, in-line with our expectations. Algeria is a top performer, with strong demand across the portfolio and a good performance from recently launched products. We are also seeing good demand in most of our other markets. Across the region, we have seen a strong rebound in demand for anti-infectives and are making progress in the launch of new products, including the launch of five locally manufactured oncology products in Algeria.

Building our global network of partners is a key area of focus for this business. We recently announced an exclusive license agreement with Almirall S.A. to commercialise FinjuveTM, a finasteride spray for the treatment of androgenic alopecia, in certain MENA markets.

We continue to expect Branded revenue growth in constant currency to be in the mid-single digits for the full year in 2021.

We will announce our preliminary results for the year ended 31 December 2021 on 24 February 2022.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.